Mid West One Financial Group, Inc. Vertex Pharmaceuticals Inc Transaction History

Mid West One Financial Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $356,720 - $427,107	-1,040 Reduced 62.95%	612 $249,000
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $183,969 - $197,178	-544 Reduced 24.77%	1,652 $574,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $57,853 - $64,751	184 Added 9.15%	2,196 $772,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $633,868 - $723,097	-2,238 Reduced 52.66%	2,012 $633,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $138,307 - $155,596	-484 Reduced 10.22%	4,250 $1.23 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $99,674 - $111,212	-364 Reduced 7.14%	4,734 $1.37 Million
Q2 2022 Aug 16, 2022	SELL	$234.96 - $292.55 $26,315 - $32,765	-112 Reduced 2.15%	5,098 $1.44 Million
Q1 2022 May 17, 2022	SELL	$221.42 - $260.97 $358,036 - $421,988	-1,617 Reduced 23.69%	5,210 $1.36 Million
Q4 2021 Feb 15, 2022	BUY	$177.01 - $223.45 $722,554 - $912,122	4,082 Added 148.71%	6,827 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $497,915 - $557,207	2,745 New	2,745 $498,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Mid West One Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Mid West One Financial Group, Inc. with notifications on news.